Trial
NCT03008616
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AMAG Pharmaceuticals, Inc.
Collaborators
—
Condition
Severe Preeclampsia
Intervention
AMAG-423 (digoxin immune fab)
Why stopped
Following a recommendation from the Data and Safety Monitoring Board (DSMB), the study was stopped early for futility. There were no safety concerns raised.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-22